MRI of the liver: choosing the right contrast agent

被引:23
|
作者
Welle, Christopher L. [1 ]
Guglielmo, Flavius F. [2 ]
Venkatesh, Sudhakar K. [1 ]
机构
[1] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA
[2] Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA
关键词
Extracellular contrast agents; Hepatobiliary contrast agents; Gadoxetate disodium; Gadobenate dimeglumine; Gadolinium-based contrast agents; Biliary tree; RESPIRATORY MOTION ARTIFACT; FOCAL NODULAR HYPERPLASIA; DISODIUM-ENHANCED MRI; HEPATOBILIARY PHASE; GADOXETATE; FIBROSIS;
D O I
10.1007/s00261-019-02162-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Contrast enhanced MRI of the liver provides valuable information in the evaluation of both chronic liver disease and focal liver lesions. Currently, two classes of MRI contrast agents are available for clinical use, namely the extracellular contrast agent (ECA) and the hepatobiliary agent (HBA). The use of appropriate contrast agents for liver MRI requires knowledge of the clinical situation and question to be answered. ECAs have been used for decades since their introduction into clinical practice and provide excellent dynamic phase information that is useful in characterizing focal liver lesions. In the last decade, HBAs, particularly Gadoxetate, have been found useful for characterizing lesions with functioning hepatocytes and more importantly in evaluating the biliary tree. Gadoxetate, however, provides less satisfactory dynamic phase images compared to ECAs, particularly during the arterial phase. In this perspective article, we will discuss the various intravenous contrast agents used for liver MRI and their ideal utilization.
引用
收藏
页码:384 / 392
页数:9
相关论文
共 50 条
  • [31] Estimation of contrast agent bolus arrival delays for improved reproducibility of liver DCE MRI
    Chouhan, Manil D.
    Bainbridge, Alan
    Atkinson, David
    Punwani, Shonit
    Mookerjee, Rajeshwar P.
    Lythgoe, Mark F.
    Taylor, Stuart A.
    PHYSICS IN MEDICINE AND BIOLOGY, 2016, 61 (19): : 6905 - 6918
  • [32] Gd-DTPA-DeA: A novel, liver-specific MRI contrast agent
    Kawamura, Y
    ACADEMIC RADIOLOGY, 2002, 9 : S102 - S103
  • [33] Gas-filled Microbubbles - A Novel Susceptibility Contrast Agent for Brain and Liver MRI
    Chow, April M.
    Cheung, Jerry S.
    Wu, Ed X.
    2009 ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-20, 2009, : 4049 - 4052
  • [34] Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging
    Xue, Shenghui
    Yang, Hua
    Qiao, Jingjuan
    Pu, Fan
    Jiang, Jie
    Hubbard, Kendra
    Hekmatyar, Khan
    Langley, Jason
    Salarian, Mani
    Long, Robert C.
    Bryant, Robert G.
    Hu, Xiaoping Philip
    Grossniklaus, Hans E.
    Liu, Zhi-Ren
    Yang, Jenny J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (21) : 6607 - 6612
  • [35] PRECLINICAL PROFILE OF GD-BOPTA - A LIVER-SPECIFIC MRI CONTRAST AGENT
    VITTADINI, G
    FELDER, E
    MUSU, C
    TIRONE, P
    INVESTIGATIVE RADIOLOGY, 1990, 25 : S59 - S60
  • [36] Choosing the right vasoactive agent for esophageal varices in cirrhosis patients
    deParades, V
    Metreau, JM
    Patri, B
    Wdowik, A
    PRESSE MEDICALE, 1997, 26 (24): : 1146 - 1148
  • [37] Choosing the right lipid-regulating agent - A guide to selection
    Farmer, JA
    Gotto, AM
    DRUGS, 1996, 52 (05) : 649 - 661
  • [38] A scale to measure MRI contrast agent sensitivity
    Rohan D. A. Alvares
    Daniel A. Szulc
    Hai-Ling M. Cheng
    Scientific Reports, 7
  • [39] Development of a paraCEST and Fluorine MRI Contrast Agent
    Ernotte, P.
    Laurent, S.
    Henoumont, C.
    INVESTIGATIVE RADIOLOGY, 2019, 54 (12) : 807 - 808
  • [40] Trends and developments in MRI contrast agent research
    Cavagna, FM
    Dapra, M
    Castelli, PM
    Maggioni, F
    Kirchin, MA
    EUROPEAN RADIOLOGY, 1997, 7 (Suppl 5) : S222 - S224